Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Novel CYP2C‐Haplotype Associated With Ultrarapid Metabolism of Escitalopram
Line Skute Bråten, Tore Haslemo, Marin M. Jukić, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 3, pp. 786-793
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Pharmacogenomics in practice: a review and implementation guide
Danya Kabbani, Reem Akika, Ahmed Wahid, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 50
Pharmacogenomics in treatment of depression and psychosis: an update
Marin M. Jukić, F. Milosavljević, Espen Molden, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1055-1069
Open Access | Times Cited: 42
Pharmacogenomics Beyond Single Common Genetic Variants: The Way Forward
Volker M. Lauschke, Yitian Zhou, Magnus Ingelman‐Sundberg
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 33-51
Open Access | Times Cited: 24
Pharmacogenetic guided drug therapy - how to deal with phenoconversion in polypharmacy?
Julia C. Stingl, Roberto Viviani
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access | Times Cited: 1
Challenges and opportunities associated with rare-variant pharmacogenomics
Yitian Zhou, Roman Tremmel, Elke Schaeffeler, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 10, pp. 852-865
Open Access | Times Cited: 32
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population
Line Skute Bråten, Magnus Ingelman‐Sundberg, Marin M. Jukić, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 9, pp. 2135-2145
Open Access | Times Cited: 21
Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity
Pablo Zubiaur, Paula Soria‐Chacartegui, Erin C. Boone, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 5, pp. 1033-1042
Open Access | Times Cited: 12
Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability
Yitian Zhou, Volker M. Lauschke
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 3, pp. 626-636
Closed Access | Times Cited: 24
A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps
Eda Eken, David Estores, Emily J. Cicali, et al.
Pharmacogenomics and Personalized Medicine (2023) Vol. Volume 16, pp. 645-664
Open Access | Times Cited: 8
Editorial: From Trial and Error to Individualised Pharmacogenomics-Based Pharmacotherapy in Psychiatry
Roos van Westrhenen, Magnus Ingelman‐Sundberg
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 16
Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial
Jan Engelmann, Lea Zillich, Josef Frank, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 12
Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus
Ping Siu Kee, Simran Maggo, Martin A. Kennedy, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 11
Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy
Luzie Eichentopf, Christoph Hiemke, Andreas Conca, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 11
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder
Erik Joas, Lina Jönsson, Alexander Viktorin, et al.
The Pharmacogenomics Journal (2022) Vol. 23, Iss. 1, pp. 28-35
Open Access | Times Cited: 9
Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics
Leticia Rodríguez-Alcolado, Pilar Navarro, Laura Arias‐González, et al.
Pharmaceutics (2024) Vol. 16, Iss. 4, pp. 487-487
Open Access | Times Cited: 1
Distribution of a novel CYP2C haplotype in Native American populations
Vanessa C. Fernandes, Marco Antônio M. Pretti, Luiza Tamie Tsuneto, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 4
Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism
Sireen Abdul Rahim Shilbayeh, Iman Sharaf Adeen, Ezzeldeen Ghanem, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics
Leticia Rodríguez-Alcolado, Pilar Navarro, Laura Arias‐González, et al.
(2024)
Open Access | Times Cited: 1
Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children
Kathryn E. Kyler, Andrea Gaedigk, Susan M. Abdel‐Rahman, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 1
Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?
Lana Ganoci, Jozefina Palić, Vladimir Trkulja, et al.
Genes (2024) Vol. 15, Iss. 5, pp. 607-607
Open Access | Times Cited: 1
Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population
Pari Faraj, Tore Haslemo, Jenny Phung Tran, et al.
British Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 1
The 75-Year Anniversary of the Department of Physiology and Pharmacology at Karolinska Institutet—Examples of Recent Accomplishments and Future Perspectives
Eddie Weitzberg, Magnus Ingelman‐Sundberg, Jon O. Lundberg, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 6, pp. 1089-1101
Open Access | Times Cited: 1
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients
Thiago Dominguez Crespo Hirata, Carolina Dagli-Hernandez, Fabiana Dalla Vecchia Genvigir, et al.
Molecular Diagnosis & Therapy (2021) Vol. 25, Iss. 6, pp. 735-755
Closed Access | Times Cited: 9
Cytochrome P450 polymorphism: From evolution to clinical use
Magnus Ingelman‐Sundberg
Advances in pharmacology (2022), pp. 393-416
Closed Access | Times Cited: 6
The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress
Ron HN van Schaik, Vangelis G. Manolopoulos, Ann K. Daly, et al.
Pharmacogenomics (2023) Vol. 24, Iss. 5, pp. 243-246
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top